Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): STC-15

            Therapeutic Area: Oncology Product Name: STC-15

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            STC-15 is an orally bioavailable, small molecule METTL3 inhibitor targeting an entirely new mechanism of action (modulation of RNA epigenetics) to treat acute myeloid leukaemia (AML) and other solid and haematological cancers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EPS 201

            Therapeutic Area: Oncology Product Name: EPS 201

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Innovate UK

            Deal Size: $1.3 million Upfront Cash: Undisclosed

            Deal Type: Funding October 21, 2020

            Details:

            Epsilogen will collaborate with King’s College London (KCL) and use the funding from the grant to further develop the company’s novel cancer immunotherapeutic EPS 201.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BT7480

            Therapeutic Area: Oncology Product Name: BT7480

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            BT7480 is a novel, fully synthetic TICA targeting Nectin-4, agonizing CD137. EphA2/CD137 TICAs are comprised of Bicycles that target the tumor antigen EphA2, which is overexpressed in a range of solid tumor types and associated with poor outcomes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SDC-1802

            Therapeutic Area: Oncology Product Name: SDC-1802

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            Details:

            The patent will protect the SDC-1802 molecule and pharmaceutical preparations thereof. Subject to certain formalities being completed, the Company expects that the patent will be granted within three months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): siRNA

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Innovate UK

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding September 23, 2020

            Details:

            Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PYTX-002

            Therapeutic Area: Oncology Product Name: PYTX-002

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Papyrus Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 17, 2020

            Details:

            The collaboration includes the assessment of the therapeutic benefit of Papyrus’ PYTX-002, a gene replacement therapy that will confer ‘cellular pharmacy’ properties on a CAR-T cell therapy developed by Oxford Biomedica, initially in preclinical in vivo models of solid tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AVA6000

            Therapeutic Area: Oncology Product Name: AVA6000

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: LG Chem

            Deal Size: $453.5 million Upfront Cash: Undisclosed

            Deal Type: Expanded Partnership August 18, 2020

            Details:

            Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta’s Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lentiviral vector

            Therapeutic Area: Oncology Product Name: LentiVector

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Beam Therapeutics Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 03, 2020

            Details:

            The DMLA grants Beam a non-exclusive license to Oxford Biomedica’s LentiVector® platform for its application in next generation CAR-T programmes in oncology and puts in place a three year Clinical Supply Agreement.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TGL-100

            Therapeutic Area: Oncology Product Name: TGL-100

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: University of Southampton

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 29, 2020

            Details:

            The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetravalent bispecific antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 16, 2020

            Details:

            This is the second license option exercised by Merck KGaA, Darmstadt, Germany who, in May 2019, brought the first program from the collaboration into its pipeline.

            PharmaCompass